Song Yuan, Wu Man-Si, Tao Gabriel, Lu Mu-Wen, Lin Jing, Huang Jun-Qing
Out-patient Department of University, the First Affiliated Hospital, Jinan University, Guangzhou 510632, PR China.
Formula-pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, PR China.
Food Res Int. 2020 Nov;137:109410. doi: 10.1016/j.foodres.2020.109410. Epub 2020 Jun 8.
Gut microbiome has been proven to be involved in the development of type 2 diabetes (T2D). Additionally, increasing evidence showed that the composition of gut microbiome is highly associated with the outcome of T2D therapy. Previously we demonstrated that feruloylated oligosaccharides (FOs) and ferulic acid (FA) alleviated diabetic syndrome in rats, but the detailed mechanism has not been explored yet. In this study we strived to characterize how FOs and FA altered the gut microbiome and related metabolome in diabetic rats by using high-throughput sequencing of 16S rRNA and gas chromatography (GC). Our results showed that FOs reduced the abundance of Lactobacillus, Ruminococcus, Oscillibacter, and Desulfovibrio, but increased the abundance of Akkermansia, Phascolarctobacterium and Turicibacter. The structure of gut microbiome in FOs treated rats was similar with healthy rats rather than diabetic rats. Likewise, FA decreased the portion of Lactobacillus, Ruminococcus, but promoted the growth of Bacteroides, Blautia, Faecalibacterium, Parabacteroides and Phascolarctobacterium. Additionally, the short-chain fatty acids (SCFAs) and branched-chain fatty acids (BCFAs), the main bacterial lipid metabolites in gut mediating host glucose metabolism, was dramatically elevated along with FOs and FA treatment. Our findings indicated that FOs and FA attenuated diabetic syndrome in rats most likely by modulating the composition and metabolism of gut microbiome. The study gives new insight into the mechanism underlying the anti-diabetes effect of functional foods as well as facilitates the development of dietary supplements for diabetic patients.
肠道微生物群已被证明与2型糖尿病（T2D）的发生发展有关。此外，越来越多的证据表明，肠道微生物群的组成与T2D治疗的结果高度相关。此前我们证明阿魏酸化低聚糖（FOs）和阿魏酸（FA）可缓解大鼠糖尿病综合征，但其具体机制尚未探讨。在本研究中，我们致力于通过16S rRNA高通量测序和气相色谱（GC）来表征FOs和FA如何改变糖尿病大鼠的肠道微生物群和相关代谢组。我们的结果表明，FOs降低了乳酸杆菌、瘤胃球菌、颤杆菌属和脱硫弧菌的丰度，但增加了阿克曼氏菌、考拉杆菌属和Turicibacter的丰度。用FOs处理的大鼠肠道微生物群结构与健康大鼠相似，而非糖尿病大鼠。同样，FA降低了乳酸杆菌、瘤胃球菌的比例，但促进了拟杆菌属、布劳特氏菌属、粪杆菌属、副拟杆菌属和考拉杆菌属的生长。此外，肠道中介导宿主葡萄糖代谢的主要细菌脂质代谢产物短链脂肪酸（SCFAs）和支链脂肪酸（BCFAs），随着FOs和FA处理显著升高。我们的研究结果表明，FOs和FA最有可能通过调节肠道微生物群的组成和代谢来减轻大鼠糖尿病综合征。该研究为功能性食品抗糖尿病作用的潜在机制提供了新的见解，并有助于开发糖尿病患者的膳食补充剂。
